Table 4 Magnitude of use of initial therapy during follow-up, by study cohort
Schizophrenia Cohort | Bipolar Cohort | |
|---|---|---|
(N = 43) | (N = 84) | |
Prescriptions | ||
Mean (SD) | 7.2 (7.4) | 4.2 (3.5) |
Median (IQR) | 5 (3, 8) | 3 (2, 6) |
Therapy-days | ||
Mean (SD) | 100.9 (69.0) | 68.3 (60.5) |
Median (IQR) | 121 (31,166) | 46 (31,115) |
MPR | ||
<10% | 8 (18.6) | 20 (23.8) |
10-20% | 6 (14.0) | 22 (26.2) |
21-30% | 1 (2.3) | 0 (0.0) |
31-40% | 2 (4.7) | 7 (8.3) |
41-50% | 0 (0.0) | 11 (13.1) |
51-60% | 2 (4.7) | 2 (2.4) |
61-70% | 4 (9.3) | 6 (7.1) |
71-80% | 4 (9.3) | 3 (3.6) |
81-90% | 6 (14.0) | 3 (3.6) |
91-100% | 10 (23.3) | 10 (11.9) |
Mean (SD) | 55.1 (37.7) | 37.3 (33.1) |
CMG | ||
<10% | 11 (25.6) | 10 (11.9) |
10-20% | 8 (18.6) | 4 (4.8) |
21-30% | 1 (2.3) | 2 (2.4) |
31-40% | 4 (9.3) | 6 (7.1) |
41-50% | 2 (4.7) | 13 (15.5) |
51-60% | 0 (0.0) | 1 (1.2) |
61-70% | 2 (4.7) | 6 (7.1) |
71-80% | 1 (2.3) | 0 (0.0) |
81-90% | 6 (14.0) | 22 (26.2) |
91-100% | 8 (18.6) | 20 (23.8) |
Mean (SD) | 44.9 (37.7) | 62.7 (33.1) |